Recent Studies Point to a Greater Role for PARP Inhibitors in Solid TumorsNovember 19th 2019
The early development of PARP inhibitors in 2003 focused on their use in combination with cytotoxic chemotherapy agents, but this was eventually abandoned because of excess toxicity.
Examining the NCCN Recommendations for Genetic Testing in Prostate CancerNovember 12th 2019
In an interview with Targeted Oncology during the 2019 Prostate Cancer Consensus Conference, James L. Mohler, MD, explained the reasons for changes to the NCCN guidelines on genetic testing and counseling in prostate cancer. He also discussed what needs to be addressed in the future to further increase knowledge of genetic testing and improve its use.
Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerNovember 12th 2019
William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Apalutamide With ADT Sustains QoL in Metastatic Castration-Sensitive Prostate CancerNovember 12th 2019
Apalutamide plus androgen deprivation therapy maintained health-related quality of life in patients with metastatic castration-sensitive prostate cancer in addition to showing positive overall survival and radiographic progression-free survival outcomes in the phase III TITAN trial, said Neeraj Agarwal, MD.
Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate CancerNovember 6th 2019
In an interview with Targeted Oncology, Alan Bryce, MD, discussed the significance of the data from PROfound for men with mCRPC. He also highlighted findings from the CARD trial and where the field is headed in terms of targeted therapies versus chemotherapies.
A Look Back at FDA News from October 2019November 1st 2019
In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Survey Shows Growing Use of Genetic Testing in Prostate Cancer Management in the CommunityOctober 28th 2019
In an interview with Targeted Oncology, Raoul S. Concepcion, MD, discussed the existing challenges with implementing genetic testing and genetic counseling in community practices and how they can potentially be addressed.
FDA Approves New Aprepitant Dosing Regimen for CINV After MECOctober 23rd 2019
The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />